Market-focused investment executive with a background in asset management, private markets and portfolio operations, Joshua Angell is experienced in deal sourcing, capital deployment and value‑creation strategies across growth and real assets. Applies a fundamentals-driven approach to risk management, capital structuring and operational improvement, supporting institutional investor relations and strategic exits while overseeing underwriting, due diligence and post-acquisition governance.
Market-focused investment executive with a background in asset management, private markets and portfolio operations, Joshua Angell is experienced in deal sourcing, capital deployment and value‑creation strategies across growth and real assets. Applies a fundamentals-driven approach to risk management, capital structuring and operational improvement, supporting institutional investor relations and strategic exits while overseeing underwriting, due diligence and post-acquisition governance.
Leans on a fundamentals-driven, market-focused investment approach that blends private markets and growth equity sensibilities with real‑asset discipline. Prefers concentrated, conviction bets sourced through direct deal origination and institutional relationships, underwriting value via rigorous due diligence, capital structuring and hands-on post-acquisition governance. Balances return-seeking with downside protection through conservative leverage, staged capital deployment and operational improvement plans; targets multi-year horizons where active oversight and exit planning unlock value across sector-agnostic opportunities with a bias toward scalable business models and tangible asset backing.
Leans on a fundamentals-driven, market-focused investment approach that blends private markets and growth equity sensibilities with real‑asset discipline. Prefers concentrated, conviction bets sourced through direct deal origination and institutional relationships, underwriting value via rigorous due diligence, capital structuring and hands-on post-acquisition governance. Balances return-seeking with downside protection through conservative leverage, staged capital deployment and operational improvement plans; targets multi-year horizons where active oversight and exit planning unlock value across sector-agnostic opportunities with a bias toward scalable business models and tangible asset backing.
| Trades 644 | Longs Won 465/644 72% | Profit Factor 7.83 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $218,283.18 |
| Average Win $85,355.9 | Best Trade (Sep 01) $3.26M | Sharpe Ratio -9.95 |
| Average Loss -$28,322.46 | Worst Trade (Mar 30) -$595,458.22 | Z-Score 10.81 (100%) |
| Commissions $0 | Avg. Trade Length 9m 2w 5d | Expectancy $53,758.96 |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% |
| Consecutive Losing Trades | 4,608 | 4,147 | 3,687 | 3,226 | 2,765 | 2,304 | 1,843 | 1,382 | 922 | 461 |
| Symbol | Quantity | Cost | Value | Comm. | Profit ($) | Gain (%) | Change |
|---|---|---|---|---|---|---|---|
AAPL Apple Inc. | 1,874 | $470,212.21 | $578,897.34 | - | $108,685.13 | 23.11% | -7.354% |
AGX Argan Inc. | 267 | $213,213 | $152,304.81 | - | -$60,908.19 | -28.57% | -1.628% |
ALIT Alight Inc. | 18,643 | $30,933.4 | $316,558.14 | - | $285,624.74 | 923.35% | -7.061% |
ALNY Alnylam Pharmaceuticals Inc | 851 | $201,973.71 | $174,897.52 | - | -$27,076.19 | -13.41% | +0.019% |
ANET Arista Networks, Inc. | 2,935 | $320,267.37 | $529,327.28 | - | $209,059.91 | 65.28% | +5.456% |
APH Amphenol Corporation | 3,796 | $234,877.5 | $305,008.6 | - | $70,131.1 | 29.86% | +0.551% |
AVDE Avantis International Equity ETF | 16,659 | $1.02M | $1.52M | - | $496,789.7 | 48.58% | -0.458% |
AVDV Avantis International Small Cap Value ETF | 82,511 | $5.49M | $8.63M | - | $3.14M | 57.26% | -0.476% |
AVEM Avantis Emerging Markets Equity ETF | 45,405 | $2.69M | $4.06M | - | $1.37M | 50.84% | +0.101% |
AVGO Broadcom Inc. | 1,645 | $376,124.15 | $640,365.6 | - | $264,241.45 | 70.25% | +0.371% |
AVRE Avantis Real Estate ETF | 15,144 | $636,581.51 | $737,512.8 | - | $100,931.29 | 15.86% | -0.754% |
AVUS Avantis U.S. Equity ETF | 144,854 | $18.32M | $18.48M | - | $165,198.01 | 0.9% | +0.567% |
AXS AXIS Capital Holdings Limited | 3,658 | $327,500.79 | $385,260.56 | - | $57,759.77 | 17.64% | +0.257% |
BAC Bank of America Corporation | 9,088 | $400,740.03 | $563,001.6 | - | $162,261.57 | 40.49% | +0.356% |
BIIB Biogen Inc. | 1,541 | $215,862.96 | $312,745.95 | - | $96,882.99 | 44.88% | -2.395% |
BIV Vanguard Intermediate-Term Bond ETF (likely mapping for ticker 0V1L) | 5,216 | $390,409.84 | $394,016.64 | - | $3,606.8 | 0.92% | -0.198% |
BKR Baker Hughes Company | 5,363 | $219,990.24 | $324,407.87 | - | $104,417.63 | 47.46% | +0.985% |
BSVO EA Bridgeway Omni Small-Cap Value Fund | 218,043 | $4.64M | $6.38M | - | $1.75M | 37.68% | -0.249% |
CFG Citizens Financial Group, Inc. | 4,968 | $217,408.31 | $355,957.2 | - | $138,548.89 | 63.73% | -0.112% |
CIEN Ciena Corporation | 1,053 | $85,640.58 | $397,033.64 | - | $311,393.06 | 363.6% | +1.338% |